Nucleotide pyrophosphatase/phosphodiesterases (NPPs) including NPP1 and NPP2/ ATX as important drug targets: A patent review (2015-2020)

References

• Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50(3):413–492.
   PubMed Web of Science ®Google Scholar
• Zimmermann H. Ectonucleotidases: some recent developments and a note on nomenclature. Drug Dev Res. 2001;52(1–2):44–56.
   Web of Science ®Google Scholar
• Zimmermann H, Zebisch M, Sträter N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal. 2012;5(3):437–502.
   Google Scholar
• Yegutkin G. Nucleotide-and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta. 2008;1783(5):673–694.
   PubMed Web of Science ®Google Scholar
• Stefan C, Jansen S, Bollen M. NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci. 2005;30(10):542–550.
   PubMed Web of Science ®Google Scholar
• Goding JW, Grobben B, Slegers H. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta. 2003;1638(1):1–19.
   PubMed Web of Science ®Google Scholar
• Stefan C, Jansen S, Bollen M. Modulation of purinergic signaling by NPP-type ectophosphodiesterases. Purinergic Signal. 2006;2(2):361–370.
   PubMedGoogle Scholar
• Albright RA, Ornstein DL, Cao W, et al. Molecular basis of purinergic signal metabolism by ectonucleotide pyrophosphatase/Phosphodiesterases 4 and 1 and implications in stroke. J Biol Chem. 2014;289(6):3294–3306.
   PubMed Web of Science ®Google Scholar
• Albright RA, Chang WC, Robert D, et al. NPP4 is a procoagulant enzyme on the surface of vascular endothelium. Blood. 2012;120(22):4432–4440.
   PubMed Web of Science ®Google Scholar
• Harmey D, Hessle L, Narisawa S, et al. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol. 2004;164(4):1199–1209.
   PubMed Web of Science ®Google Scholar
• Goldfine ID, Maddux BA, Youngren JF, et al. The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocr Rev. 2008;29(1):62–75.
   PubMed Web of Science ®Google Scholar
• Stefan C, Wera S, Stalmans W, et al. The inhibition of the insulin receptor by the membrane protein PC-1 is not specific and results from the hydrolysis of ATP. Diabetes. 1996;45(7):980–983.
   PubMed Web of Science ®Google Scholar
• Zhao T, Liu Z, Zhang D, et al. The ENPP1 K121Q polymorphism is not associated with type 2 diabetes or obesity in the Chinese Han population. J. Hum. 2011;56(1):12–16.
   Google Scholar
• Aerts I, Martin JJ, De Deyn PP, et al. The expression of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (E-NPP1) is correlated with astrocytic tumor grade. Clin Neurol Neurosurg. 2011;113(3):224–229.
   PubMed Web of Science ®Google Scholar
• Li L, Yin Q, Kuss P, et al. Hydrolysis of 2ʹ3’-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol. 2014;10:1043–1048.
   PubMed Web of Science ®Google Scholar
• Tao J, Zhou X, Jiang Z, et al. cGAS-cGAMP-STING: the three musketeers of cytosolic DNA sensing and signaling. IUBMB Life. 2016;68(11):858–870.
   PubMed Web of Science ®Google Scholar
• Li J, M.a D, Dhanota N, et al. Metastasis and immune evasion from extracellular cGAMP hydrolysis. Cancer Discov. 2021;11(5):1212–1227.
   PubMed Web of Science ®Google Scholar
• A AR, Stabach P, Cao W, et al. ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy. Nature Commun. 2015;6(1):1–11.
   Google Scholar
• R SP, Zimmerman K, Adame A, et al. Improving the pharmacodynamics and in vivo activity of ENPP1‐Fc through protein and glycosylation engineering. Clin Transl Sci. 2021;14(1):362–372.
   PubMed Web of Science ®Google Scholar
• Carozza JA, Böhnert V, C NK, et al. Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity. Nat Cancer. 2020;1(2):184–196.
   PubMedGoogle Scholar
• Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem. 1992;267(4): 2524–2529.
   PubMed Web of Science ®Google Scholar
• Hausmann J, Kamtekar S, Christodoulou E, et al. Structural basis for substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol. 2011;18(2):198–204.
   PubMed Web of Science ®Google Scholar
• Nishimasu H, Okudaira S, Hama K, et al. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol. 2011;18(2):205–212.
   PubMed Web of Science ®Google Scholar
• van Meeteren LA, Ruurs P, Stortelers C, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol. 2006;26(13):5015–5022.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Okudaira S, Kishi Y, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 2006;281(35):25822–25830.
   PubMed Web of Science ®Google Scholar
• Fotopoulou S, Oikonomou N, Grigorieva E, et al. ATX expression and LPA signalling are vital for the development of the nervous system. Dev Biol. 2010;339(2):451–464.
   PubMed Web of Science ®Google Scholar
• Giganti A, Rodriguez M, Fould B, et al. Murine and human autotaxin α, β, and γ Isoforms: gene organization, tissue distribution, and biochemical characterization. J Biol Chem. 2008;283(12):7776–7789.
   PubMed Web of Science ®Google Scholar
• Ferry G, Tellier E, Try A, et al. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation: up-regulated expression with adipocyte differentiation and obesity. J Biol Chem. 2003;278(20):18162–18169.
   PubMed Web of Science ®Google Scholar
• Sato K, Malchinkhuu E, Muraki T, et al. Identification of autotaxin as a neurite retraction-inducing factor of PC12 cells in cerebrospinal fluid and its possible sources. J Neurochem. 2005;92(4):904–914.
   PubMed Web of Science ®Google Scholar
• Tokumura A, Kume T, Fukuzawa K, et al. Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity. Life Sci. 2007;80(18):1641–1649.
   PubMed Web of Science ®Google Scholar
• Nochi H, Tomura H, Tobo M, et al. Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells. J Immunol. 2008;181(7):5111–5119.
   PubMed Web of Science ®Google Scholar
• Oikonomou N, Mouratis MA, Tzouvelekis A, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012;47(5):566–574.
   PubMed Web of Science ®Google Scholar
• Nikitopoulou I, Oikonomou N, Karouzakis E, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med. 2012;209(5):925–933.
   PubMed Web of Science ®Google Scholar
• Kanda H, Newton R, Klein R, et al. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol. 2008;9(4):415–423.
   PubMed Web of Science ®Google Scholar
• Fuss B, Baba H, Phan T, et al. Phosphodiesterase I, a novel adhesion molecule and/or cytokine involved in oligodendrocyte function. J Neurosci. 1997;17(23):9095–9103.
   PubMed Web of Science ®Google Scholar
• Moolenaar WH. Lysophospholipids in the limelight: autotaxin takes center stage. J Cell Biol. 2002;158(2):197–199.
   PubMed Web of Science ®Google Scholar
• Koike S, Keino-Masu K, Ohto T, et al. The N-terminal hydrophobic sequence of autotaxin (ENPP2) functions as a signal peptide. Genes Cells. 2006;11(2): 133–142.
   PubMed Web of Science ®Google Scholar
• Lee SY, Müller CE. Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors. Med Chem Comm. 2017;8(5):823–840.
   Google Scholar
• Lee SY, Namasivayam V, Boshta NM, et al. Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno) therapy. RSC Med Chem. 2021;12(7):1187–1206.
   PubMedGoogle Scholar
• Lopez V, Lee SY, Stephan H, et al. Recombinant expression of ecto-nucleotide pyrophosphatase/phosphodiesterase 4 (NPP4) and development of a luminescence-based assay to identify inhibitors. Anal Biochem. 2020;603:113774.
   PubMed Web of Science ®Google Scholar
• Gorelik A, Randriamihaja A, Illes K, et al. A key tyrosine substitution restricts nucleotide hydrolysis by the ectoenzyme NPP 5. FEBS J. 2017;284(21):3718–3726.
   PubMed Web of Science ®Google Scholar
• Morita J, Kano K, Takita H, et al. Structure and biological function of ENPP6, a choline-specific glycerophosphodiester-phosphodiesterase. Sci Rep. 2017;6(1):1–14.
   Google Scholar
• Gorelik A, Liu F, Illes K, et al. Crystal structure of the human alkaline sphingomyelinase provides insights into substrate recognition. J Biol Chem. 2017;292(17):7087–7094.
   PubMed Web of Science ®Google Scholar
• Al-Rashida M, Qazi SU, Batool N, et al. Ectonucleotidase inhibitors: a patent review (2011-2016). Expert Opin Ther Pat. 2017;27(12):1291–1304.
   PubMed Web of Science ®Google Scholar
• Chang L, Lee SY, Leonczak P, et al. Imidazopyridine- and purine-thioacetamide derivatives: potent inhibitors of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1. J Med Chem. 2014;57(23):10080–10100.
   PubMed Web of Science ®Google Scholar
• Lee SY, Muller CE. Nucleotide Pyrophosphatase/Phosphodiesterase 1 (NPP1) and Its Inhibitors. MedChemComm. 2017;8(5):823–840.
   PubMed Web of Science ®Google Scholar
• Zelikman V, Pelletier J, Simhaev L, et al. Highly selective and potent ectonucleotide pyrophosphatase-1 (NPP1) inhibitors based on uridine 5’-Pα, α-dithiophosphate analogues. J Med Chem. 2018;61(9): 3939–3951.
   PubMed Web of Science ®Google Scholar
• Vankayalapati H, Liu X, Ramamoorthy G, et al. U.S. Patent No. 10,689,376. Washington (DC): U.S. Patent and Trademark Office; 2020.
   Google Scholar
• Fronthera US. Pharmaceuticals LLC Autotaxin inhibitors and uses thereof. WO2019228403. 2019.
   Google Scholar
• Suzhou Sinovent Pharmaceuticals. Heterocyclic compounds, application thereof and pharmaceutic composition comprising same. WO2019158107. 2019.
   Google Scholar
• Roche H-L. Heterocyclic inhibitors of ATX. WO2020119896. 2020
   Google Scholar
• Jing TF, Miao XQ, Jiang F, et al. Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors. Bioorg Med Chem. 2018;26(8):1784–1796.
   PubMed Web of Science ®Google Scholar
• Shenyang Pharmaceutical University. Indol-based ATX inhibitors and methods of preparing and using thereof. CN111187261. 2020.
   Google Scholar
• Pharmakea Inc. Heterocyclic autotaxin inhibitor compounds. 2016. WO2016144704.
   Google Scholar
• Shanxi Institute of Biology. Carbazole compounds as autotaxin inhibitors and preparation method thereof and uses thereof. CN107266356. 2017.
   Google Scholar
• University of Tennessee Research Foundation. Autotaxin inhibitors. WO2017210527. 2017.
   Google Scholar
• Fells JI, Lee SC, Fujiwara Y, et al. Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipaseD as an inhibitory surface. Mol Pharmacol. 2013;84(3):415–424.
   PubMed Web of Science ®Google Scholar
• Roche H-L. Heterocyclic compounds useful as dual ATX/CA inhibitors. WO2018167001. 2018.
   Google Scholar
• Nagano T, Okabe T, Kojima H, et al. U.S. Patent No. 10,189,843. Washington (DC): U.S. Patent and Trademark Office; 2019.
   Google Scholar
• Di Giorgio P, Hert J, Hunziker D, et al. U.S. Patent No. 9,802,944. Washington (DC): U.S. Patent and Trademark Office; 2017.
   Google Scholar
• WO2020022470 - Novel 3, 5-Disubstituted Pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same.
   Google Scholar
• Mitsubishi Tanabe Pharma Corporation. Novel 3,5-disubstituted pyridine and 3,5-disubstituted pyridazine derivatives and pharmaceutical use of same. WO2020022470. 2020.
   Google Scholar
• Boehringer Ingelheim International GmbH. Novel pyridazines. US20200131151. 2020.
   Google Scholar
• Lee G, Kang SU, Ryou JH, et al. BBT-877, a potent autotaxin inhibitor in clinical development to treat idiopathic pulmonary fibrosis. PAT. 2019;505:100.
   Google Scholar
• MacKenna D, Shannon KE, Nguyen KT, et al. PAT-409, a novel inhibitor of autotaxin, reduces fibrosis in both mouse and rat models of NASH. J Hepatol. 2017;66:214A–214A.
   Google Scholar
• Deken M, Niewola-Staszkowska K, Lahn MM, et al. IOA-289, a Novel, Clinical Stage Autotaxin Inhibitor for the Treatment of Fibrotic Lung Disease Am J Respir Crit Care Med. ;2021;203:A1332 .
   Web of Science ®Google Scholar
• Zimmermann H. Extracellular ATP and other nucleotides—ubiquitous triggers of intercellular messenger release. Purinergic Signal. 2016;12(1):25–57.
   PubMed Web of Science ®Google Scholar
• Tan Z, Lei H, Guo M, et al. An updated patent review of autotaxin inhibitors (2017–present). Expert Opin Ther Pat. 2021;31(5):421–434.
   PubMed Web of Science ®Google Scholar